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Summary
Background: Cartilage destruction in osteoarthritis (OA) involves the excessive degradation and increased synthesis of cartilage matrix mac-
romolecules including type II collagen (CII) and proteoglycans. The lack of osteophytes (atrophic form of OA) has been shown to be a disease
severity factor in hip OA. Since osteophyte formation involves endochondral ossiﬁcation and a cartilage intermediate, atrophic OA may also
exhibit differences in cartilage turnover compared to hypertrophic OA. Cartilage serum biomarkers may offer an opportunity to identify such
differences in patients.
Aim: To determine whether serum levels of cartilage biomarkers can distinguish between the presence and absence of osteophyte formation
in patients with atrophic and hypertrophic hip OA.
Patients and methods: Fifty-six patients (mean age/standard deviation (SD): 62/11; mean body mass index (BMI)/SD: 27/11) with symptom-
atic hip OA (American College of Rheumatology criteria; mean Lequesne index/SD: 8.3/4) were classiﬁed as having an atrophic or hypertro-
phic form of OA, according to the absence or presence, respectively, of any osteophyte on a standard radiograph of the pelvis. Minimum joint
space width (minJSW) and angles of dysplasia [centre-edge (CE) and head-neck-shaft (HNS)] were determined by computerized measure-
ments.
The following serum markers were used which are commercial kits from Ibex Diagnostics (Montreal, QC): proteoglycan aggrecans turnover:
CS 846; CII synthesis: C-propeptide (CPII), cleavage by collagenase of type II (C2C) and type I and II (C1,2C) collagens.
Statistics: Patients with atrophic and hypertrophic OA were compared for each variable and step to step logistic regression was used to de-
termine the effect of variables on the belonging to each group. Correlations were examined using linear regression or Spearman test.
Results: CPII serum levels were signiﬁcantly lower in the atrophic OA patients (77.3 vs 117.4 ng/mL). There were no signiﬁcant differences
between groups for C2C, C1,2C and CS 846 . CPII and C2C concentrations were highly correlated in hypertrophic OA (P¼ 0.002) but not in
atrophic OA (P¼ 0.8).
Conclusion: Atrophic hip OA is characterized by reduced synthetic activity involving type II collagen synthesis. This could account in part for
the absence of osteophyte formation. The highly signiﬁcant correlation between CPII and C2C in hypertrophic but not in atrophic OA suggests
that the physiological coupling between CII formation and degradation may be lost in atrophic OA. These differences may therefore help ex-
plain the absence of osteophyte in atrophic OA and its association with more rapid disease progression.
ª 2006 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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International
Cartilage
Repair
SocietyOsteoarthritis (OA) is anatomically deﬁned as involving fo-
cal articular cartilage destruction, combined with osteophyte
formation. The latter involves the subchondral bone and the
process of endochondral new bone formation at the joint
margin. The latter may be a ‘‘reparative’’ response to joint
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2006.46damage and altered mechanical loading and an adaptative
reaction of the joint instability.
Nevertheless the onset and the progression of cartilage
loss, osteophyte formation can occur at different rates and
differ widely among patients and joints1. The hip is one of
the jointsmost frequently affected byOA in adults of 55 years
and older2, often leading to the need for total hip arthroplasty
in the late stages of the disease. However the rate of pro-
gression of hip OA is very heterogenous among patients
as demonstrated by number of studies3e6. Solomon7
suggested that the behaviour of coxarthrosis may be deter-
mined by three interacting factors such as cartilage degener-
ation, excessive mechanical stress, and reparative bone2
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features are dominant, cartilage loss is localised, remodel-
ling is good and the hip can stabilise. When inﬂammatory
and degenerative features predominate, reparative new
bone formation is minimal and progression is more rapid.
The pattern involving cartilage and bone changes can be
classiﬁed as hypertrophic or atrophic according to the pres-
ence or the absence of osteophytes, respectively8. There is
strong evidence that the atrophic form is a major factor fa-
vouring the severity of hip OA as demonstrated by a faster
progression of joint space narrowing (JSN) than in hypertro-
phic OA8,9. This rapid progression may be related to a lack
of reparative processes and/or to abnormally elevated
levels of cartilage destruction creating an imbalance be-
tween synthesis and degradation.
Because type II collagen (CII) is the most abundant pro-
tein of cartilage matrix, the assessment of CII synthesis and
degradation may be of value in the study of OA progression.
Moreover, it would be important to study type I collagen
degradation as well as CII since type I is the predominant
collagen of bone, a component of osteophyte formation
and structure.
Biological biomarkers are now available to study types I
and II collagen turnover in vivo. To assess CII degradation,
we measured serum concentrations of the neo-epitopes
C2C (type II) and C1,2C (type I) generated by collage-
nases10,11. CII biosynthesis was evaluated by measuring
the C-propeptide of type II collagen12 (CPII) whereas the
turnover of the cartilage proteoglycan aggrecan was mea-
sured using the proteoglycan CS 846 assay13,14.
The aim of the present study was to determine whether
these biomarkers reﬂect metabolic differences between atro-
phic and hypertrophic patterns of hipOAwhichmay then help
in our understanding of the pathophysiology of the disease.
Subjects and methods
PATIENTS
This prospective cross-sectional caseecontrol study was
conducted in 56 patients (34 women, 22 men) of mean age
[standard deviation (SD)]: 62 [11.1] years (range: 44e95
years) who met the American College of Rheumatology cri-
teria for primary hip OA15. All patients but two were Cauca-
sians. Patients with hip OA secondary to alternative
arthropathies were excluded (i.e., infectious or inﬂammatory
arthritis, aseptic osteonecrosis, Paget disease and major
congenital abnormalities such as congenital dislocation of
the hip). All patients underwent a full clinical examination
to record the following information: height, weight, body
mass index (BMI), disease duration, polyarticular OA in-
volvement (Heberden or Bouchard’s nodes, radiological e
(if X-rays available) e spine OA or knee OA). Pain was
self-assessed by the patients on a 100 mm visual analog
scale (VAS) and disability relative to hip OA was evaluated
using the Lequesne algofunctional index16. None of the pa-
tients presented with any other clinically detectable disease
that may inﬂuence biomarker levels. None of the patients
received steroid or hyaluronic acid intra-articular injection
in the previous 3 months. For each patient, all clinical radio-
logical and laboratory data were obtained on a single day.
RADIOGRAPHIC DATA
All patients underwent radiographs of the pelvis, using
a standardized procedure. Antero-posterior (AP) radio-
graphs of the pelvis were performed in standing positionwith 20 of internal rotation of the lower limbs. The focus-
ﬁlm distance was 100 cm and the beam was aligned to
the top of pubic symphysis. Lequesne ‘‘faux-proﬁl’’ (FP) of
the two hips was also performed using the standardized
procedure17.
Morphological evaluation: Radiographic changes were
graded according the modiﬁed Altman score18,19 using
a ﬁve point scale (0e4) for JSN, a four point scale (0e3)
for osteophytes, a three point scale (0e2) for cysts and
a two point scale (0e1) for sclerosis. The selected score
was the highest one obtained from the two radiological
views (AP or FP). Inter-observer kappa value (95% CI)
was 0.91 (0.88e0.94), 0.79 (0.71e0.87), 0.77 (0.67e0.87)
and 0.76 (0.68e0.85) for each item, respectively19.
Each hip was then classiﬁed as hypertrophic or atrophic
according to presence or absence of osteophytes. To be
classiﬁed as atrophic, the hip had to be of grade 0 for osteo-
phyte and >1 for JSN. To be classiﬁed as hypertrophic it
must be of grade >1 for both JSN and osteophyte.
The intra-class coefﬁcient of correlation (95% CI) be-
tween repeated evaluations was 0.96 (0.91e0.99)9. The
pattern of femoral head migration within the acetabulum
was classiﬁed as supero-lateral, supero-intermediate,
supero-medial or inferior as proposed by Ledingham et al.8.
JOINT SPACE MEASUREMENT
Joint space width (JSW) was measured using a novel
version of a software whose results were previously pub-
lished20. The new version (Holy’s software-ß16, Lyon,
France) uses an edge-based algorithm that automatically
detects the joint space contours. Standing AP hip X-rays
were digitized in a BMP format at a resolution of 300 ppi
(giving a pixel size of 0.08 mm). The region in which the
measurement was performed was delineated within a 60
angle whose summit was the centre of the femoral head
(automatically given by the computer from three peripheral
points drawn by the reader using the mouse) and whose
landmarks are the internal boundary and the non-osteo-
phytic external edge of the acetabulum (obtained by a single
click by the reader).
Within this angle, the joint space contours detection was
automatically performed by the gradient algorithm and both
minimum and mean JSW (minJSW, meanJSW) were auto-
matically calculated. When the algorithm failed to delineate
the contours the reader could also correct the computer-
drawn contours as appropriate, by drawing them with the
mouse.
Reproducibility of JSW measurement was assessed from
the repeated measurement of 50 hip radiographs. The root-
mean-square SD (RMS-SD) was 0.013 and 0.006 for
minJSW and meanJSW, respectively, giving a coefﬁcient of
variation (CV) for minJSW and meanJSW of 0.57% and
0.27%, respectively. The intra-class coefﬁcient of correlation
was 0.99. The SD for repeated measurements of the same
ﬁlmwas0.17 and 0.12 mmso that the smallest detectable dif-
ference was 0.34 and 0.24 mm (2SD) for minJSW and
meanJSW, respectively. Patterns of hip joint dysplasia:
head-neck-shaft angle (HNS), acetabular depth (AD) and
centre-edge (CE) angle were also obtained using the
computer.
BIOCHEMICAL MEASUREMENTS
Blood samples were obtained from each subject on the
day the radiographs were taken and the clinical evaluation
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at 25C.
The samples were thawed once to aliquot them and re-
frozed. Then they were thawed again to assay them.
The Enzyme linked immunosorbent assay biomarker as-
says were obtained from IBEX (Montreal, Canada). Their
use and reproducibility for serum has been described in de-
tail21.The following assays were used. The C2C assay em-
ploys a mouse monoclonal antibody that recognizes the
carboxy-terminal neo-epitope generated by the cleavage
of CII by collagenases10.
The C1,2C assay uses a polyclonal rabbit antibody that
recognizes the carboxy-terminal neo-epitope generated by
the cleavage of collagenases in both I and II collagens11.
The CS 846 assay measures an epitope on the chondroi-
tin sulphate chains of aggrecan molecules.
The CPII assay measures the synthesis of type II colla-
gen12. Results for all assays are expressed as ng/ml.
The intraassay reproducibility of measurements of con-
centrations of C2C, CPII, C1,2C and CS 846 was 9.7%,
6.4%, 10% and 11.5%, respectively.
STATISTICS
A computer database containing all measured data was
created in StatViewª 5.0 (SAS Institute Inc) format. Statisti-
cal analyses were performed using the following proce-
dures: patients with atrophic and hypertrophic OA were
compared for each variable using the chi-squared test, Stu-
dent’s t test or Mann and Whitney test as appropriate. Step
to step logistic regression (including sex, age, BMI and the
variables that were statistically related to a group in the uni-
variate analysis) was used to determine the effect of quan-
titative data on the belonging to each group. Correlations
between quantitative data were studied using linear regres-
sion or Spearman test as appropriate. P values <0.05 were
considered statistically signiﬁcant.
Results
Among the 56 patients, 14 fulﬁlled the criteria for atrophic
OA and 42 for hypertrophic OA. In the total population no
correlation was found between biomarkers and clinical or
demographic data except for BMI and C1,2C that were
weakly correlated (P¼ 0.05).
None of the biomarkers was related to the radiological se-
verity (minJSW, meanJSW or any score), nor to any other
clinical parameters.
Table I summarizes the differences between the two sub-
groups in both univariate and multivariate analyses.In the univariate analysis, there was no signiﬁcant differ-
ence between the two groups regarding age, sex ratio,
pain and disability, bilaterality, generalized OA and any
of the biomarkers. BMI and CE angle were higher in the
hypertrophic group whereas meanJSW (but not minJSW)
and HNS angle were signiﬁcantly larger in the atrophic
group. However logistic regression revealed that serum
concentrations of CPII were signiﬁcantly higher in the
hypertrophic group (P< 0.004) (Fig. 1). The logistic re-
gression estimates in Table I represent the signiﬁcant vari-
ables from a single stepwise model including all variables,
and show that meanJSW and CE angle were also signiﬁ-
cantly and independently related to the pattern of bone
response.
In the hypertrophic group CPII and C2C were correlated
(Spearman test: Rho¼ 0.48, P¼ 0.002) whereas there
was no correlation in the atrophic group (Rho¼ 0.07,
P¼ 0.78) (Fig. 2). C2C and C1,2C were correlated in both
groups (Rho¼ 0.69 and 0.38; P¼ 0.01 and 0.02 for atro-
phic and hypertrophic OA, respectively) (Fig. 3) while CS
846 and CPII were correlated only in atrophic OA
(Rho¼ 0.7, P¼ 0.01). There were no associations of the
CS 846 epitope with other biomarkers or clinical
parameters.
Discussion
The present data suggest that the lack of osteophyte
formation and the more rapid progression that distin-
guishes a particular subgroup called atrophic hip OA
may result from a deﬁciency in the synthetic (reparative)
processes involving CII, in view of the selective reduction
in the level of CPII, a marker of type II collagen synthesis.
Cartilage proteoglycan turnover was unchanged demon-
strating the selectivity of the collagen differences. The dis-
tinctive pathology of atrophic OA therefore may be due in
part to the inability for the chondrocytes to synthesize new
CII in sufﬁcient amount in response to increased cartilage
breakdown. The coupling between CII cleavage by colla-
genases and synthesis which was observed in hypertro-
phic OA was absent in atrophic hip OA. This no doubt
contributes to the differences. On the other hand we did
not ﬁnd that the biomarkers of collagen degradation were
different compared with the common form hypertrophic
OA. Also, the C2C and C1,2C epitopes were correlated
in both groups. Whether this indicates that overall bone
and cartilage collagen cleavage remain coupled irrespec-
tive of other changes remains to be established with other
more speciﬁc assays for bone resorption. The deﬁciency in
cartilage collagen synthesis and lack of coupling withTable I
Biological, demographics and radiological differences between atrophic and hypertrophic hip OA. The logistic regression estimates represent
the significant variables from a single stepwise model including all variables
Variables Units N Atrophic [median
(mean/SD)]
N Hypertrophic
[median(mean/SD)]
Univariate
analysis (P)
Logistic
regression (P)
C2C ng/mL 14 9.9 (10.1/2.9) 42 10.6 (10.9/2.9) 0.43
C1,2C ng/mL 14 85 (110/89.8) 42 123 (157.6/108.6) 0.15
CPII ng/mL 14 77.3 (93.7/50.7) 42 117.4 (132.6/75.2) 0.07 0.004
CS 846 ng/mL 14 196.1(225.2/144.6) 42 232.9 (301/192.5) 0.19
Age years 14 57 (58.6/11.8) 42 64 (61.9/10) 0.23
BMI kg/m2 13 23 (23.7/3) 41 26 (27.5/5.5) 0.03
MeanJSW mm 14 3.5 (3.4/1.15) 42 2.5 (2.68/1.13) 0.06 0.04
CE angle ( 14 26.7 (26.8/7.3) 42 36.5 (36.6/11.4) 0.01 0.002
HNS angle ( 13 139.5 (138.9/6.4) 41 128.5 (128.7/7.7) 0.0009
465Osteoarthritis and Cartilage Vol. 15, No. 4degradation may, however, contribute to the overall pathol-
ogy including the lack of osteophytes. These are formed
through a process of endochondral bone formation that in-
volves a cartilage intermediate and is therefore dependant
upon active cartilage collagen synthesis, coupled to carti-
lage resorption22.
Very little has been published on this topic. In two previ-
ous studies we found that serum bone sialoprotein (BSP)
serum concentrations (reﬂective of bone turnover) were in-
versely correlated with osteophyte score19 but we did not
observe any difference between atrophic and hypertrophic
hip OA or associations with these conditions when serum
hyaluronic acid, cartilage oligomeric matrix protein, collage-
nase, type I collagen, C-terminal cross linking telopeptide of
type I collagen, tissue inhibitor of metalloproteases-1
and C reactive protein were examined9.
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Fig. 1. Difference of collagen II propeptide (CPII) serum concentra-
tions between atrophic and hypertrophic hip OA.Two other markers of CII degradation were previously
demonstrated to be reﬂective of the progression of hip
OA. Urinary C telopeptide of type II collagen (CTX-II) and
Helix II23,24 are increased in rapidly destructive OA (also fre-
quently associated with the absence of osteophytes), sug-
gesting that a sustained increased rate of CII destruction,
as assessed by these speciﬁc urinary biomarkers, would
lead to more rapid destruction of cartilage. Other studies
have shown that of different molecular markers of bone,
cartilage and synovium turnover, urinary CTX-II was the
most predictive for assessing the progression of knee
OA25 and that an uncoupling of CII synthesis and degrada-
tion was also predictive of joint damage progression26. The
present biomarkers were not examined in this study.
It has also been reported that a combination of a biochem-
ical marker of type II collagen synthesis (serum type IIA col-
lagen N-propeptide) and degradation (CTX-II) was more
effective than one of these two markers alone to predict dis-
ease progression in knee OA23 and that combining a marker
of synovitis (serum hyaluronic acid) with CTX-II improved
prediction of disease progression in hip OA27. Thus, it
may be useful to combine markers of different metabolic
processes (e.g., synthesis and degradation of cartilage
CII) and/or markers of turnover of different joint tissues
(synovium and cartilage), and/or markers of different molec-
ular mechanisms of cartilage degradation, to better under-
stand the mechanisms of progression in OA.
Our study has, however, some limitations. This cross-
sectional study did not directly examine progression of hip
OA and the association of progression with these markers.
The levels of these markers may wax and wane over time
with activity of disease and a single sample may not be ad-
equate to characterize progression. Indeed the atrophic
CPII measurements appear to have a bimodal distribution
in the atrophic population. This suggests that relative pe-
riods of quiescence would have lower levels in the serum.
The number of patients is also limited, and the status of
other potential sources of CII markers, such as the knees,
hands and spine, was not fully evaluated and could have
confounded the results28. Furthermore the design of the
study made us unable to take into account the potential ef-
fects of treatments and physical activity. Either variable can
affect biomarker levels. A ﬁnal point requires some discus-
sion. It is unclear whether the serum measurements we
have made involving these biomarkers reﬂect cartilage turn-
over as a consequence of hip pathology or a reﬂection ofP=0.78
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Fig. 2. Correlation between collagen II propeptide (CPII) and collagen II neo-epitope C2C serum concentrations in atrophic and hypertrophic
hip OA.
466 T. Conrozier et al.: Differences in biomarkers of CII in atrophic and hypertrophic OA of the hipsystemic differences in cartilage metabolism that predis-
pose towards these differences in pathology. It may well
be the latter but this remains to be seen.
In summary, atrophic pathology in hip OA might be due to
a lack of a deﬁciency in synthetic process involving CII and
a lack of coupling between the synthesis and degradation
of this molecule. Prediction of phenotype and progression
based on this combination of markers will need to be formally
assessed in larger groups preferably over a period of years.
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